Form 4: Essa Pharma COO Sells Shares Under 10b5-1 Trading Plan

Peter Virsik, COO of Essa Pharma Inc., sold 694 common shares at a weighted average price of $6.95 on May 6, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 6, 2024, Peter Virsik, the Chief Operating Officer of Essa Pharma Inc., sold 694 common shares of the company.
• The sale was executed at a weighted average price of $6.95 per share.
• This transaction was conducted under a pre-existing 10b5-1 trading plan established on August 31, 2023.
• Following the transaction, Mr. Virsik directly owns 11,246 common shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through mechanisms like 10b5-1 trading plans to avoid accusations of trading on material non-public information. The market typically views these sales in the context of the overall insider ownership and the reasons behind the sale.

Stakeholder Impact

• The sale of shares by a company officer could have a minor impact on shareholder confidence, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates